ストックスクリーナーアプリを入手
78.26
0.10%
0.08
アフターアワーズ：
78.26
前日終値:
$78.18
開ける：
$78.39
24時間の取引高:
2.62M
Relative Volume:
0.61
時価総額：
$45.95B
収益：
$5.69B
当期純損益:
$1.41B
株価収益率:
11.26
EPS:
6.95
ネットキャッシュフロー:
$577.90M
1週間 パフォーマンス:
-0.11%
1か月 パフォーマンス:
+1.89%
6か月 パフォーマンス:
+2.72%
1年 パフォーマンス:
+14.89%
1日の値動き範囲:
$77.58
$78.50
1週間の範囲:
$76.07
$78.50
52週間の値動き範囲:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
名前
Edwards Lifesciences Corp
セクター
電話
(949) 250-2500
住所
ONE EDWARDS WAY, IRVINE, CA
EW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-29 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-04-24 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | アップグレード | Stifel | Hold → Buy |
| 2025-01-16 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-09-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-31 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-07-25 | ダウングレード | Truist | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2024-05-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-03-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-02-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-28 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-03-29 | 開始されました | UBS | Neutral |
| 2023-03-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | ダウングレード | Bernstein | Outperform → Underperform |
| 2023-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | ダウングレード | Stifel | Buy → Hold |
| 2022-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 開始されました | Mizuho | Buy |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 開始されました | Truist | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-03-16 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-27 | 繰り返されました | Citigroup | Buy |
| 2022-01-27 | 繰り返されました | Evercore ISI | Outperform |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Buy |
| 2022-01-27 | 繰り返されました | UBS | Neutral |
| 2021-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-12-15 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-12-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-30 | 繰り返されました | Deutsche Bank | Hold |
| 2021-07-30 | 繰り返されました | Jefferies | Buy |
| 2021-07-30 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-07-30 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-30 | 繰り返されました | Stifel | Buy |
| 2021-07-30 | 繰り返されました | UBS | Neutral |
| 2021-07-30 | 繰り返されました | Wells Fargo | Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-04-05 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-11 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Underperform |
| 2020-04-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Outperform |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-09-23 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-24 | 繰り返されました | BofA/Merrill | Buy |
| 2019-03-18 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-01-18 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 開始されました | Deutsche Bank | Hold |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-16 | 開始されました | Barclays | Underweight |
| 2018-10-02 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | ダウングレード | Guggenheim | Buy → Neutral |
すべてを表示
Edwards Lifesciences Corp (EW) 最新ニュース
FTC Sues to Block Edwards LifeSciences Medical Device Deal - MSN
Edwards Lifesciences’ TRISCEND II Trial: A Game-Changer in Tricuspid Valve Treatment? - MSN
Stock Analysis | Edwards Lifesciences OutlookNavigating Mixed Signals in a Volatile Landscape - AInvest
Edwards Lifesciences Hits $0.2B Trade Volume Amid Trial Progress Ranks 479th in Daily Activity - AInvest
Edwards Lifesciences’ ENCIRCLE Trial: A New Hope for Mitral Regurgitation Patients - TipRanks
Edwards Lifesciences’ TRISCEND Study: A Game-Changer in Tricuspid Valve Replacement? - TipRanks
FTC Moves to Block Edwards Lifesciences’ $945 Million Acquisition of JenaValve Over Competition Concerns - MSN
FTC to block Edwards Lifesciences’ acquisition of JenaValve due to competitive concerns - 富途牛牛
Edwards Lifesciences Rebounds on Institutional Buys Despite Securities Probe as $220M Volume Ranks Among Top 500 - AInvest
Edwards Lifesciences Advances with SAPIEN X4 Heart Valve Study - TipRanks
EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Edwards Lifesciences Rises 0.97% Amid 427th-Ranked Trading Volume as Fundamentals and Technicals Clash - AInvest
Moody’s revises Edwards Lifesciences outlook to positive, affirms Baa2 - Investing.com
Moody’s revises Edwards Lifesciences outlook to positive, affirms Baa2 By Investing.com - Investing.com Canada
Edwards Lifesciences Stock: Analyst Estimates & Ratings - inkl
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences Ranks 458th in Trading Volume as Institutional Splits and High-Return Strategy Highlight Volatile Market Dynamics - AInvest
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - MSN
FTC Sounds Alarm On Edwards' Attempt To Corner Heart Device Market - Benzinga
Edwards Lifesciences Leads Heart Device Market With Value Upside - Finimize
Edwards Lifesciences’ ALT-FLOW II Trial: A Key Update for Heart Failure Treatment - TipRanks
Baird Adjusts Price Target on Edwards Lifesciences to $81 From $79, Maintains Neutral Rating - MarketScreener
FTC moves to block Edwards’ acquisition of JenaValve Technology - Medical Buyer
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve - WKZO
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
FTC sues to block Edwards Lifesciences purchase of JenaValve - MSN
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve | Business Information & News | FE - Westlaw Today
Bank Groups Urge Congress to Close ‘Loopholes’ in GENIUS Act - PYMNTS.com
FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - The Wall Street Journal
Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says - MLex
FTC moves to block Edwards Lifesciences’ JenaValve acquisition - MassDevice
JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition - The Manila Times
Jenavalve disagrees with FTC's decision against proposed Edwards Lifesciences deal - MarketScreener
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
Edwards Lifesciences Fights FTC Block of JenaValve Deal as EPS Guidance Jumps to $2.55 - Stock Titan
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga
Edwards Lifesciences Corporation's (NYSE:EW) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - Jammu Links News
Is Edwards Lifesciences Corporation a growth stock or a value stockHigh-octane investment gains - Jammu Links News
What catalysts could drive Edwards Lifesciences Corporation stock higher in 2025Build wealth with professional market analysis - Jammu Links News
Is it the right time to buy Edwards Lifesciences Corporation stockSuperior portfolio returns - Jammu Links News
How many analysts rate Edwards Lifesciences Corporation as a “Buy”Strongest growth potential - Jammu Links News
Edwards Lifesciences Corp (EW) 財務データ
収益
当期純利益
現金流量
EPS
0.35%
1.24%
大文字化:
|
ボリューム (24 時間):